U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations.
作者信息
Zuabi Nadia, Patel Bhavesh, Langdorf Mark I
机构信息
University of California, Irvine, School of Medicine, Irvine, California.
University of California, Irvine, School of Biological Sciences, Irvine, California.
出版信息
West J Emerg Med. 2016 Nov;17(6):741-746. doi: 10.5811/westjem.2016.8.31197. Epub 2016 Sep 12.
Abstract
摘要
相似文献
1
U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations.美国食品药品监督管理局：急诊医生对审批流程及局限性的审查
West J Emerg Med. 2016 Nov;17(6):741-746. doi: 10.5811/westjem.2016.8.31197. Epub 2016 Sep 12.
2
FDA science: from concept to consumer.
FDA Consum. 2004 May-Jun;38(3):10-1.
3
Missing evidence.证据缺失。
MLO Med Lab Obs. 2008 Oct;40(10):68.
4
Teaching the elephant to dance: privatizing the FDA review process.教大象跳舞：使美国食品药品监督管理局（FDA）的审评流程私有化。
Food Drug Law J. 1996;51(4):651-76.
5
The 21st Century Cures Act: can the regulatory framework survive the "cures"?《21世纪治愈法案》：监管框架能否经受住“治愈”的考验？
Cad Saude Publica. 2015 Sep;31(9):1807-10. doi: 10.1590/0102-311XPE010915.
6
Understanding physician responsibilities and limitations for drug and device off-label use.了解医生在药品和器械非标签使用方面的责任与局限性。
Facial Plast Surg Clin North Am. 2007 May;15(2):251-4, viii. doi: 10.1016/j.fsc.2007.01.010.
7
Demystifying the U.S. Food and Drug Administration: understanding regulatory pathways.揭开美国食品药品监督管理局的神秘面纱：了解监管途径。
Plast Reconstr Surg. 2014 Sep;134(3):559-569. doi: 10.1097/PRS.0000000000000477.
8
Has the food and drug administration changed the drug approval process?美国食品药品监督管理局是否改变了药品审批程序？
Am J Ther. 2011 May;18(3):179. doi: 10.1097/MJT.0b013e31822076ed.
9
Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation.医生对美国食品药品监督管理局（FDA）批准标准的了解以及对“突破性疗法”认定的看法。
JAMA. 2016 Apr 12;315(14):1516-8. doi: 10.1001/jama.2015.16984.
本文引用的文献
1
Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?专利“常青化”是否限制了药品/器械组合产品的可及性？
PLoS One. 2016 Feb 24;11(2):e0148939. doi: 10.1371/journal.pone.0148939. eCollection 2016.
2
Switching from CFC to HFA Inhalers: What NPs and Their Patients Need to Know.从含氯氟烃吸入器转换为氢氟烷烃吸入器：执业护士及其患者需要了解的事项。
Am J Nurse Pract. 2009 Oct;13(10):45-50.
3
The 21st Century Cures Act--Will It Take Us Back in Time?《21世纪治愈法案》——它会让我们倒退吗？
N Engl J Med. 2015 Jun 25;372(26):2473-5. doi: 10.1056/NEJMp1506964. Epub 2015 Jun 3.
4
Effect of Direct-to-Consumer Advertising on Asthma Medication Sales and Healthcare Use.直接面向消费者的广告对哮喘药物销售和医疗保健使用的影响。
Am J Respir Crit Care Med. 2015 Jul 1;192(1):40-6. doi: 10.1164/rccm.201409-1585OC.
5
The relationship between direct to consumer advertising (DTCA) and asthma-related emergency department use among Medicaid-enrolled children.医疗补助计划参保儿童中直接面向消费者的广告（DTCA）与哮喘相关的急诊科就诊之间的关系。
J Asthma. 2014 Nov;51(9):922-6. doi: 10.3109/02770903.2014.930880. Epub 2014 Jun 20.
6
Pharmaceuticals, political money, and public policy: a theoretical and empirical agenda.药品、政治献金与公共政策：理论与实证研究议程
J Law Med Ethics. 2013 Fall;41(3):561-70. doi: 10.1111/jlme.12065.
7
2012 trends and statistics for prescription medications in the United States: CNS therapeutics continue to hold leading positions.2012年美国处方药的趋势与统计数据：中枢神经系统治疗药物继续占据领先地位。
ACS Chem Neurosci. 2013 Aug 21;4(8):1133-5. doi: 10.1021/cn400127u.
8
Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?直接面向消费者的药品广告：有益还是有害？
P T. 2011 Oct;36(10):669-84.
9
Patent protection strategies.专利保护策略
J Pharm Bioallied Sci. 2010 Jan;2(1):2-7. doi: 10.4103/0975-7406.62694.
10
Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants.含氯氟烃推进剂的沙丁胺醇吸入器的撤市
N Engl J Med. 2007 Mar 29;356(13):1344-51. doi: 10.1056/NEJMra050380.
Zotero 插件